Pergamum AB, a portfolio company of Karolinska Development AB, has finalized the Clinical Study Report of a randomized Phase I/II trial of LL-37 for treatment of venous leg ulcers. Patients treated with LL-37 had a statistically significant improved healing rate compared with placebo and no safety or tolerability concerns were noted, confirming the positive preliminary data reported in July 2013. LL-37 is a human peptide that is involved in acute wound healing. Data from independent research gr...